Modern virtual and augmented reality device can help simulate sight loss

March 10, 2020

Published today, during World Glaucoma Week 2020, a new study demonstrates how commercially available head mounted displays (HMD) can be used to simulate the day-to-day challenges faced by people with glaucoma.

Glaucoma is an umbrella term for a group of degenerative eye diseases that affect the optic nerve at the back of the eye. It is the leading cause of irreversible blindness worldwide, and is estimated to represent 11% of cases of serious sight impairment in the UK1.

The study, from the Crabb Lab, at City, University of London, suggests potential applications of the technology could include helping policymakers better assess the impact of visual impairment on patients, and helping architects to design more accessible buildings.

Twenty-two volunteers who did not have glaucoma took part in the study. Participants wore a HMD while performing various tasks in either virtual or augmented reality.

In the virtual reality task, participants were placed in a simulation of a typical, 'cluttered' house. Moving their eyes and head allowed them to look around it in order to find a mobile phone hidden somewhere in the house.

In the augmented reality task, participants navigated a real-life, human-sized 'mouse maze', which they viewed through cameras in the front of the HMD.

Sensors in the HMD tracked the position of the participant's eyes, allowing the software to generate a blurred area of vision, known as a 'scotoma', that obstructed the same portion of their visual field, wherever they looked.

The scotoma was created using medical data from a real glaucoma patient, and either restricted vision in the upper part of the participant's visual field, or in the bottom part. In 'control' trials the scotoma was absent.

Similar to real glaucoma patients, participants were slower to perform the tasks when the simulated impairment was present, and made more head and eye movements too. They likewise found the tasks particularly difficult when the vision loss obstructed the bottom part of their visual field. The results also showed how some people were better able to cope than others with an identical impairment.

The software the authors created to simulate the visual impairment (OpenVisSim) has been shared online for others to freely use and develop. It is compatible with most commercially available HMDs and smartphones, and supports a range of visual effects, designed to simulate the different symptoms associated with a range of eye diseases.

First author of the study, Dr Peter Jones, Lecturer at the Crabb Lab, City, University of London, said:

"While it's impossible to recreate exactly what it's like to have glaucoma, our findings suggest that digital simulators can at least allow people to experience some of the challenges that people with glaucoma face every day. We are now working with architects to explore whether sight-loss simulators can be used design more accessible buildings and transport systems."

The study is published in the online journal, npj Digital Medicine.
-end-
Notes to editors

Contact details:

To speak to Dr Peter Jones contact Senior Communications Officer, School of Health Sciences, Shamim Quadir: Tel: 0207 040 8782 email: shamim.quadir@city.ac.uk.

Alternatively, contact the City, University of London Press Office at pressoffice@city.ac.uk or on 020 7040 8788.

The study was funded by Moorfields Eye Charity (https://moorfieldseyecharity.org.uk/) and Fight for Sight (UK) (https://www.fightforsight.org.uk/)

Reference:

1. Quartilho, A., Simkiss, P., Zekite, A., Xing, W., Wormald, R. and Bunce, C., 2016. Leading causes of certifiable visual loss in England and Wales during the year ending 31 March 2013. Eye, 30(4), p.602.

Read the full research article on the npj Digital Medicine website:

https://www.nature.com/articles/s41746-020-0242-6

Dr Peter Jones has written a blog to accompany the research article on the npj Digital Medicine website:

https://go.nature.com/38tmiRO

The OpenVisSim software is freely available to download online:

https://github.com/petejonze/OpenVisSim

Video (Youtube, March, 2020). Watch the OpenVisSim demonstration of simulations of visual impairments filmed at City TECS (Technology Enabled Care Studio), City, University of London:

https://www.youtube.com/watch?v=LEGkGHwb_Fw

An online tool showcasing effects possible with OpenVisSim: https://www.ucl.ac.uk/~smgxprj/vr/

More on the Crabb Lab at City, University of London: Website: http://www.staff.city.ac.uk/crabblab/#/ Twitter: @crabblab

About City, University of London

City, University of London is a global higher education institution committed to academic excellence, with a focus on business and the professions and an enviable central London location.

City's academic range is broadly-based with world-leading strengths in business; law; health sciences; mathematics; computer science; engineering; social sciences; and the arts including journalism and music.

City has around 20,000 students (46% at postgraduate level) from more than 160 countries and staff from over 75 countries.

In the last REF, City doubled the proportion of its total academic staff producing world-leading or internationally excellent research.

More than 140,000 former students from over 180 countries are members of the City Alumni Network.

The University's history dates from 1894, with the foundation of the Northampton Institute on what is now the main part of City's campus. In 1966, City was granted University status by Royal Charter and the Lord Mayor of London became its Chancellor. In September 2016, City joined the University of London and HRH the Princess Royal became City's Chancellor.

Led by President, Professor Sir Paul Curran since 2010, City has made signi?cant investments in its academic staff, its estate and its infrastructure and continues to work towards realising its vision of being a leading global university: it has recently agreed a new Vision & Strategy 2026.

City University London

Related Glaucoma Articles from Brightsurf:

Monitoring glaucoma at home
Glaucoma is a chronic condition that affects cells at the back of the eye.

Study finds novel mechanism that may confer protection against glaucoma
A team of researchers from LSU Health New Orleans Neuroscience Center of Excellence and the University of Copenhagen provides the first evidence that patients with ocular hypertension may exhibit superior antioxidant protection that promotes resistance to the elevated intraocular pressure associated with glaucoma.

AI-supported test for very early signs of glaucoma progression
A new test can detect glaucoma progression 18 months earlier than the current gold standard method, according to results from a UCL-sponsored clinical trial.

New method gives glaucoma researchers control over eye pressure
Neuroscientists have developed a new method that permits continuous regulation of eye pressure without damage, becoming the first to definitively prove pressure in the eye is sufficient to cause and explain glaucoma.

Glaucoma care in prison inmates
Data fromĀ 82 prison inmates treated in a glaucoma clinic at an academic hospital were used in this observational study to report on how treatment and follow-up, including medication adherence, were are managed.

New glaucoma test to help prevent blindness
Researchers have identified 107 genes that increase a person's risk of developing the eye disease glaucoma, and now developed a genetic test to detect those at risk of going blind from it.

Air pollution linked to higher glaucoma risk
Living in a more polluted area is associated with a greater likelihood of having glaucoma, a debilitating eye condition that can cause blindness, finds a new UCL-led study in the UK.

Long-term statin use associated with lower glaucoma risk
A new study brings the connection between statin use and risk of glaucoma into sharper focus.

Health burden of glaucoma has risen worldwide
The health burden of glaucoma has continuously increased around the globe in the past 25 years, according to an Acta Opthalmologica study.

UAlberta scientists first to pinpoint a cause of pigmentary glaucoma
An international team of researchers has identified a gene responsible for the onset of pigmentary glaucoma, which may lead to new therapies for the condition.

Read More: Glaucoma News and Glaucoma Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.